Vertex Reports Q1 Revenue of $3 Billion, Driven by Strong Performance of New Cystic Fibrosis Therapies, Despite Kasgevy and Journavx Sales Falling Short of Expectations
Q1 Performance and the Generational Shift in the Cystic Fibrosis Market
Vertex Pharmaceuticals (VRTX) reported Q1 revenue of $3 billion, slightly below Wall Street's expectations. While its core revenue driver remains Trikafta (elexacaftor/tezacaftor/ivacaftor) for Cystic Fibrosis, sales reached $2.35 billion, a 7% decrease year-over-year. However, its next-generation triple combination therapy, Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), generated $424 million in sales, an 8-fold increase year-over-year. This demonstrates a successful 'healthy switching' trend in the market, with existing Trikafta patients rapidly transitioning to the new therapy.
Initial Sales of New Commercial Products Fall Short, Market Analysis
Despite high market expectations, the initial performance of Casgevy (exagamglogene autotemcel), the first CRISPR-Cas9 gene editing therapy, and Journavx (suzetrigine), a non-opioid pain reliever, fell short of expectations. Casgevy, approved for Sickle Cell Disease and Beta Thalassemia, generated $43 million in sales this quarter, 10% below market forecasts. Journavx, a NaV1.8 sodium channel inhibitor, generated $29 million in sales, 18% below expectations. This is attributed to the high initial cost of innovative therapies, complex administration procedures, and limited reimbursement coverage for acute pain.
Accelerated Approval of Next-Generation Pipeline Candidate Povetacicept
Investors are closely watching Povetacicept, Vertex's key pipeline candidate and a dual BAFF and APRIL inhibitor. Vertex recently submitted a Biologics License Application (BLA) to the FDA for accelerated approval for the treatment of Immunoglobulin A Nephropathy (IgA Nephropathy, IgAN), which has been accepted. In the Phase 3 RAINIER trial, Povetacicept demonstrated impressive efficacy, reducing proteinuria by 52.0% from baseline at week 36. With the FDA's Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026, this is expected to be a major catalyst to offset the company's short-term performance.
Clinical Differentiation Strategy for Inaxaplin Amidst Intensifying Competition
Vertex's other late-stage pipeline candidate, the APOL1 inhibitor Inaxaplin (VX-147), is progressing well in Phase 3 trials for the treatment of genetic APOL1-mediated kidney disease (AMKD). Recently, competitor Maze Therapeutics announced positive topline results from a Phase 2 trial of its APOL1 inhibitor, MZE829, intensifying market competition. However, Vertex is aiming for accelerated approval by securing interim data in early 2027 from a global Phase 2/3 trial encompassing both pediatric and adult patients. As a leader in the kidney disease market, Vertex aims to leverage these clinical results to fend off Maze's challenge and maintain its leading position.
This Q1 performance highlights the potential for a generational shift in Vertex's $110 billion market cap, while also reflecting market concerns about the pace of commercial adoption for Kasgevy and Journavx. In the short term, the FDA PDUFA accelerated approval date of November 30, 2026, for BAFF/APRIL dual inhibitor Povetacicept, and the long-term data from the Phase 3 RAINIER trial, are expected to be key catalysts for a stock rebound. In the medium to long term, the success of Inaxaplin, currently in Phase 3 trials, in maintaining its leading position in the kidney disease market against Maze Therapeutics' MZE829 will be crucial. Furthermore, the outcome of the application for expanded approval of Kasgevy for pediatric patients with Sickle Cell Disease (SCD), with Vertex and CRISPR Therapeutics sharing a 60/40 revenue split, will serve as an indicator of the potential market size for rare blood disease gene therapies.
Source: BioPharma Dive (rss)